7 trends tracked about this subject — the full history, oldest to newest below.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly targets the illicit market for its unapproved obesity drug retatrutide through new legal actions.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.